



1Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, USA
*Correspondence: paul.tesar@case.edu
http://dx.doi.org/10.1016/j.stemcr.2015.12.011
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARY
Pluripotency is a unique developmental state that lays the founda-
tion upon which the entire embryo is built. Pluripotent cells
possess the unique capacity to generate, in an exquisitely defined
sequence, all the distinct cell types comprising the fetal and adult
organism. The discovery of pluripotent stem cells and now the
ability to generate them from differentiated cells has had a pro-
found impact on a vast array of scientific disciplines. In addition
to their clinical potential as a source of therapeutic cell types,
pluripotent stem cells provide scalable access to otherwise experi-
mentally inaccessible development- and disease-associated
biology. Here I providemyperspective on the continuumof plurip-
otency in the early mammalian embryo. I also discuss how novel
genomic technologies are now enabling the capture of molecular
‘‘snapshots’’ of the several distinct pluripotent states that stem cells
undergo during this pivotal developmental period.
The Continuum of Pluripotency in the Mouse Embryo
The development of placental mammals is unique in that
embryos are nourished by interfacing with the mothers’
reproductive tract, in contrast to embryos of other classes
of vertebrates that develop outside the womb. Thus,
mammalian embryos must generate extra-embryonic cell
types to mediate their implantation into the uterus, while
at the same time maintain a distinct population of unspec-
ified pluripotent cells to form the embryo proper. To do so,
within 5 days of fertilization, the mouse zygote partitions
itself into three separate cell populations, the trophoecto-
derm, primitive endoderm, and epiplast, which carry out
these diverse tasks in concert. The developmental potential
of each of these cell populations was defined by seminal ex-
periments in which chimeric embryos were generated by
cell transplantation into host blastocysts (Gardner, 1968;
Gardner and Rossant, 1979; Rossant et al., 1978). These
studies, among others, showed conclusively that trophec-
toderm cells form the bulk of the fetal portion of the
placenta, primitive endoderm cells generate the parietal
and visceral yolk sac endoderm, and epiblast cells generate
the entire embryo proper as well as additional extra-embry-
onic tissues such as the amnion and allantois.
Several pioneering studies have shown that epiblast cells
in thepre- andpost-implantationepiblast function tomain-
tainpluripotencyuntil theonset of gastrulation.During im-
plantation, the trophectoderm invades thematernaluterine
tissue to provide sustained access to nutrient and waste ex-
change for the remainder of gestation. At this point, theStem Cepost-implantation epiblast changes from a small cluster of
cells into a pseudostratified epithelium that must remain
unspecified while it prepares to differentiate into all of the
early somatic and germ cell fates that appear during gastru-
lation. Evidence that that the post-implantation epiblast is
capable of generating cell fates from each of the three pri-
mary germ layers was provided by experiments in which it
was transplanted to ectopic sites in adult mice (Diwan and
Stevens, 1976). Thesedatawere later supportedby fate-map-
ping studies revealing that individual cells of the post-im-
plantation epiblast were not lineage restricted and could
contribute to all three germ layers, even when transplanted
from one spatial region of the post-implantation epiblast to
another (Lawson et al., 1991; Tam and Zhou, 1996).
Historically, pluripotency was considered a single state,
yet it was clear quite early on that epiblast cells before
and after implantation were morphologically and func-
tionally dissimilar. In contrast to cells of the pre-implanta-
tion epiblast, cells of the post-implantation epiblast did not
readily incorporate back into host blastocysts or contribute
to the developing embryo in standard chimera assays
(Gardner et al., 1985). In retrospect, this observation
demonstrated a clear developmental distinction between
pre- and post-implantation epiblast cells and provided
the first indication that more than one shade of pluripo-
tency might exist.The Two Dominant Pluripotent Attractor States
It only became possible to study pluripotency and its prop-
erties when, in 1981, two groups concurrently reported
that they had derived pluripotent cells from mouse pre-
implantation blastocyst stage embryos, and that these
cells could be expanded indefinitely in culture in an undif-
ferentiated state (Evans and Kaufman, 1981; Martin,
1981). Remarkably, these mouse embryonic stem cells
(mESCs), later shown to originate from the pre-implanta-
tion epiblast (Brook and Gardner, 1997), could be induced
to differentiate into a plethora of functional cell types
spanning all three germ layers. Later, stringent in vivo as-
says confirmed the pluripotency of mESCs by showing
that when injected into host blastocysts, they integrated
into the developing embryo and contributed to all cell
types of the resulting chimeric mice, including the germ-
line (Bradley et al., 1984; Nagy et al., 1993). Since then,
pluripotent stem cell lines have been derived from earlierll Reports j Vol. 6 j 163–167 j February 9, 2016 j ª2016 The Authors 163
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Perspectiveblastomere and morula stage mouse embryos, as well as
primordial germ cells (Matsui et al., 1992; Resnick et al.,
1992; Tesar, 2005). Later, in a series of groundbreaking
studies, it was shown that even adult somatic cells can
be ‘‘reprogrammed’’ to a pluripotent state by forcing
expression of what are now known as core pluripotency
transcription factors, yielding induced pluripotent stem
cells (iPSCs) (Takahashi and Yamanaka, 2006). Pluripotent
cells derived from each of these methods are subtly
different in terms of their epigenome, yet remarkably,
they show almost identical functional properties. Collec-
tively, these studies support the notion that a single
pluripotent state, referred to as naive pluripotency, can164 Stem Cell Reports j Vol. 6 j 163–167 j February 9, 2016 j ª2016 The Aube captured in vitro from mouse embryos or reprog-
rammed from mouse somatic and germ cells.
In the meantime, pivotal advances were being made in
defining pluripotency in human cells. In 1998, human
ESCs (hESCs) were isolated for the first time from human
blastocyst stage embryos and, like their mouse counter-
parts, could be renewed indefinitely in culture while main-
taining their pluripotent state (Thomson et al., 1998). This
achievement marked the beginning of the path for
advancing pluripotent stem cells into the clinic for regener-
ative medicine. In a remarkably short time, this goal has
been realized, with a number of clinical trials using hESCs
to regenerate damaged or diseased tissues and organs now
underway.
Yet despite being derived from identical blastocyst stages,
hESCs were perplexingly distinct from their murine coun-
terparts in their morphology, molecular profiles, and their
need for different signaling molecules to maintain them
in an undifferentiated state (Daheron et al., 2004; James
et al., 2005; Smith et al., 1988; Vallier et al., 2005; Ying
et al., 2003, 2008). Initially, these differences were largely
overlooked and attributed to minor species-specific varia-
tion, as opposed to reflecting true significance in the
inherent developmental origin and capacity of each cell
type.
Then, in 2007, two studies reporting a new type ofmouse
stem cell type transformed the understanding of pluripo-
tency (Brons et al., 2007; Tesar et al., 2007). The cells,
termed epiblast stem cells (EpiSCs), were initially isolated
from early post-implantation mouse and rat embryos just
prior to gastrulation. In contrast, mESCs characterized in
earlier studies were derived from pre-implantation em-
bryos. However, although mouse EpiSCs showed striking
similarity to native post-implantation epiblast cells, they
did not readily incorporate into the developmentally
earlier blastocyst in mouse chimeric embryos. Yet EpiSCs
were clearly pluripotent, as demonstrated by in vitro differ-
entiation, teratoma generation, and transplantation into
the peri-gastrulation epiblast of in vitro cultured whole
mouse embryos (Brons et al., 2007; Huang et al., 2012;
Tesar et al., 2007).
These data led to a major shift in how pluripotency is
defined. What had previously been defined as the pluripo-
tent state based on the earlier mouse ESC studies repre-
sented only a common attractor state inherent to pluripo-
tent cells derived from the mouse pre-implantation
epiblast, referred to as naive pluripotency (Nichols and
Smith, 2009). EpiSCs, on the other hand, represent a
distinct pluripotent state, referred to as primed pluripo-
tency, based on morphological, molecular, and functional
criteria. Most strikingly, EpiSCs derived from mice shared
defining properties with hESCs. This observation led to
the current understanding that standard hESC linesthors
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embryos from which they are derived.
Once it was recognized that distinct pluripotent subtypes
do exist, the study of epiblast-derived pluripotent stem
cells soared. Now there is an exciting body of work showing
that EpiSCs represent a previously undefined attractor state
of pluripotency. To date, EpiSCs have been derived from a
spectrum of post-implantation stages up through the early
phase of gastrulation (Bernemann et al., 2011; Han et al.,
2010; Kojima et al., 2014; Wu et al., 2015). In addition,
induced EpiSCs (iEpiSCs) have been derived by reprogram-
ming somatic cells with core pluripotency transcription
factors in culture conditions distinct from iPSC derivation
(Han et al., 2011). Surprisingly, by controlling the culture
environment, EpiSCs could even be isolated from pre-im-
plantation mouse blastocysts, which strongly supports
the notion that what are currently defined as hESCs prog-
ress in culture to this second pluripotent attractor state
representative of the post-implantation epiblast (Hanna
et al., 2009; Najm et al., 2011).
Why mammals in particular evolved to have more than
one pluripotent state during embryogenesis remains an
open question. Other vertebrates such as fish and frogs
have what appears to be a single pluripotent state akin to
themouse post-implantation epiblast just prior to gastrula-
tion. While purely speculative, it is tempting to consider
that the pre-implantation pluripotent state evolved as a
mammalian-specific trait to ensure fidelity of the pluripo-
tent cells until a sustained source of nourishment upon im-
plantation in the uterus could be acquired. In line with this
idea,manymammals are known to be able to delay implan-
tation of embryos and maintain them in a dormant state,
termed embryonic diapause, until favorable conditions
are present that enhance the survival of the mother and
offspring (Renfree and Shaw, 2000). Upon implantation,
the pluripotent cells then transition from a naive state of
cellular fidelity to a primed state in which the cells are pre-
pared to rapidly respond to developmental cues and transi-
tion into the full complement of somatic and germ cells
fates during gastrulation.
Importance of Naive and Primed Pluripotent Stem
Cells
The array of pluripotent stem cell lines derived directly
from mouse and human blastocysts and through reprog-
ramming provides a scalable source of differentiated cells
representing the full spectrum of cell fates, embryonic
and extra-embryonic. The ability to readily derive these
cells from healthy and diseased mice and humans is trans-
forming cell-based regenerative medicine and providing
unprecedented tools for modeling and developing drugs
for a variety of previously intractable, incurable chronic
diseases. Thus, a pressing question for the field is whetherStem Cenaive or primed pluripotent stem cells are better suited to
these tasks and for use as experimental tools for under-
standing the mechanistic basis for pluripotency and
differentiation.
All pluripotent stem cell lines are capable of providing a
source of scalable somatic cell fates for studying their
biology, and for disease modeling and cell-based regenera-
tive medicine. Initially, experimenters decided whether to
use naive versus primed pluripotent stem cells based on
technical advantages that varied depending on the experi-
mental requirements, including the ability to expand them
from isolated single cells, their amenability to homologous
recombination-based genome editing, their genetic acces-
sibility, and the uniformity of their differentiation
response. However, recent advances in culture conditions
and nuclease-mediated genome editing have largely obvi-
ated technical limitations for both cell types, enabling
focus on their true biological differences.
Consequently, the door has now been opened for com-
plementary studies employing both of these distinct
pluripotent states, providing unprecedented access to the
molecular events occurring at the earliest phases of
mammalian development that were not possible by study-
ing naive or primed cells in isolation.
In particular, global epigenetic and transcriptome com-
parisons between mESCs and mEpiSCs have revealed new
insights into naive and primed pluripotency including the
molecular mechanisms that maintain pluripotent cells in
an undifferentiated statewhile remaining permissive to dif-
ferentiation into all somatic and germ cell lineages. While
these two pluripotent states exhibit a relatively small num-
ber of differentially expressed genes, they differ substan-
tially in the organization of their chromatin landscape,
particularly with respect to covalent histone modifications
of cis-regulatory elements such as enhancers, DNAmethyl-
ation, and the binding pattern of pluripotency transcrip-
tion factors (Buecker et al., 2014; Factor et al., 2014).
Surprisingly, in each of the two cell states, mESCs and
EpiSCs, genes with the same levels of expression, including
core pluripotency factors such as Oct4, are controlled by
distinct enhancer elements (Factor et al., 2014; Tesar et al.,
2007; Yeom et al., 1996). Moreover, naive pluripotent cells
such as mESCs do not require expression of any of the cata-
lytically active DNA methyltransferases, whereas primed
cells show a clear dependence on proper establishment
and maintenance of DNA methylation (Liao et al., 2015).
Collectively, these global comparisons suggest that the
transition from naive to primed pluripotency is predomi-
nantly controlled by changes in chromatin organization.
Initially, in naive pluripotent cells, the chromatin is
organized is such a way that it that safeguards the cells
from inappropriate differentiation, maintaining them in a
pluripotent state. Then as the cells become primed, thell Reports j Vol. 6 j 163–167 j February 9, 2016 j ª2016 The Authors 165
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to transition to a somatic regulatory program during
gastrulation.
Our understanding of the mechanisms controlling addi-
tional developmental events in the early mammalian em-
bryo has been uniquely advanced by the combined utility
of naive and primed pluripotent stem cell biology. For
example, there exists a narrow window in the early post-
implantation embryo when a handful of founder primor-
dial germ cells (PGCs) are specified from the epiblast (Hay-
ashi et al., 2007). In the past, attempts to generate PGCs
directly from naive and primed pluripotent stem cells
yielded limited success. But recently, by leveraging under-
standing of the two pluripotent stem cells states, groups
have now robustly generated mouse and human primor-
dial germ cell-like cells in vitro from cells in a transitionary
state between naive and primed termed epiblast-like cells
(EpiLCs) (Hayashi et al., 2007; Irie et al., 2015). In addition,
comparison of female naive mESCs and primed EpiSCs has
enabled new understanding of the initiation and mainte-
nance of X chromosome inactivation in female somatic
cells (Gayen et al., 2015).
Conclusions
The two dominant pluripotent stem cells states have pro-
vided powerful in vitro snapshots of the mammalian plu-
ripotency continuum. Utilization of these in vitro cell
states provides unprecedented access to fundamental
developmental events that have previously been inacces-
sible to large-scale molecular analyses. Although we have
already seen pluripotent stem cell studies yield two Nobel
Prizes, we have likely only scratched the surface of what
pluripotent stem cell biology will yield in terms of funda-
mental understanding of development and disease as well
as clinical applications.ACKNOWLEDGMENTS
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